CellPly, the pioneer in multiparametric single-cell analysis and automated potency testing for cell therapy, recently announced the appointment of Emiliano Spagnolo to the role of CEO. Spagnolo joins CellPly after 15 years at Comecer Group, a company commercializing automated solutions for pharmaceutical products manufacturing, including Advanced Therapeutics Medicinal Products (ATMP), where he drove above-market growth for multiple business lines. Spagnolo succeeds current CellPly CEO and founder Massimo Bocchi, who will be moving into a Chief Strategy Officer role with the company.
Emiliano Spagnolo on his appointment
“Having spent the last 15 years growing the Comecer Group from a family-owned company to a multinational group, I’m excited by the tremendous potential in CellPly capabilities and the VivaCyte Platform to accelerate our understanding of cancer and to enable novel cell and gene therapy development with biopharma partners,” said Emiliano Spagnolo, CEO of CellPly.
Massimo Bocchi on his tenure
“The 9 years I spent leading CellPly have been an incredible journey, I am thankful to the investors who believed in our initial idea leaving me the opportunity to guide an extraordinary team in making this idea an actual product,” said Massimo Bocchi, Cellply founder and Chief Strategy Officer. “Emiliano shares our vision about the opportunity to revolutionize the development of cell therapies and immunotherapies by characterizing the immune system function at the single-cell level. He also recognizes the uniqueness of the world-class technical team that throughout the years developed a game-changer technology with passion, motivated by the ambition to support the development of life-saving therapies. Emiliano will bring Cellply to the next level by combining this technical expertise with the commercial and operational growth that the company needs to be a key player in a global market,” added Bocchi.
Before joining CellPly, Spagnolo led the commercial organization at Comecer and the opening of subsidiaries in India, China, Emirates and USA. He also led the transition of Comecer into ATS Automation Group having the opportunity to be part of strategic teams managing M&A operations and company integrations.
Board Chair’s comments on the new appointment
“We are excited to get Emiliano on board with us,” said Alessia Zanelli, Chair of the Board at CellPly. “We are all looking forward for extraordinary results during the coming years of Cellply thanks to his experience together with the rest of the entire team at Cellply,” added Zanelli.
More news about healthcare, and health and wellness sectors:
Biosyngen opens new cell therapy GMP facility in Singapore
Top 10 trends in the global spa industry
Axsome Therapeutics announces selling of common stock in a public offering
Dr. Liu Jian joins Medicilon as President of Drug Discovery Division
Katja Conrath appointed as Chief Scientific Officer
HKSTP and AstraZeneca sign MOU on Strategic Collaboration
